Physician profile
Roberta Stanhope
NPI 1720231616
$7,638.83
in general payments reported to CMS, 2019-2025
21 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 92% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,472 · 2022: $1,210 · 2023: $1,584 · 2024: $1,730 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,956.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $1,380.16 | 2023-2025 | Auvelity |
| Abbvie INC. | $1,058.89 | 2021-2025 | |
| Alkermes, INC. | $945.12 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $848.88 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $831.22 | 2021-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $585.12 | 2021-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $374.01 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $333.37 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $276.19 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $186.38 | 2024 | Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $137.39 | 2022 | |
| Ironshore Pharmaceuticals INC. | $124.16 | 2021 | |
| Corium, LLC | $118.93 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $110.14 | 2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $83.97 | 2023-2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $62.63 | 2022 | |
| Lundbeck LLC | $53.14 | 2022-2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $43.99 | 2021 | |
| Pfizer INC. | $31.87 | 2023 | |
| Vanda Pharmaceuticals INC. | $30.38 | 2022 | |
| Ibsa Pharma INC. | $22.89 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Stanhope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.